1. Volume 148, Issue 1, Pages 79-85 (January 2018)
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients 
V. Heinzelmann-Schwarz, A. Knipprath Mészaros, S. Stadlmann, F. Jacob, A. Schoetzau, K. Russell, M. Friedlander, G. Singer, M. Vetter 
Gynecologic Oncology 
Volume 148, Issue 1, Pages (January 2018)
DOI: /j.ygyno
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1
ESR1 expression in TCGA dataset. Overall disease-free survival (A) and relapse-free survival (B) in the TCGA PANCAN dataset (Cohort A, Table 1) p-value (log rank test). (C) Box-Whisker blot ESR1 expression for anatomical origin sorted by descending median ESR1 expression among all TCGA cancer types; (D) ESR1 expression for histopathological grading and FIGO staging in the Tothill and TCGA data set for high-grade serous ovarian cancer samples (Cohort A, Table 1). (E) Barchart showing percentage of IHC results for ER and PR in HGSOC broken down into various sampling sites (Cohort B, Table 1).
Gynecologic Oncology  , 79-85DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Relapse-free survival of HGSOC FIGO III/IV treated with/without Letrozole as a maintenance therapy. Letrozole treated (red line; n=23) vs untreated group (black line; n=27), showing a significantly longer relapse-free survival when using Letrozole (p=0.035). RFS is defined from the end of adjuvant chemotherapy till first symptomatic recurrence, confirmed by RECIST. IC50 not reached in the Letrozole vs untreated group (13.2months) (Cohort D; Table 1).
Gynecologic Oncology  , 79-85DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Relapse-free survival of HGSOC FIGO III/IV treated with Bevacizumab as a maintenance therapy. Letrozole treated (red line; n=9) vs untreated group (black line; n=6), showing a significantly longer relapse-free survival when using Letrozole in combination with Bevacizumab in patients with residual disease (p=0.026). RFS is time from end of adjuvant chemotherapy until first symptomatic relapse as confirmed by RECIST.
Gynecologic Oncology  , 79-85DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions